CIPLA vs PFIZER: Stock Comparison

Cipla Ltd vs Pfizer Limited

Live data: 22 July 2026, 2:34 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Pfizer Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Pfizer Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 2 of 11 scored metrics and PFIZER on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹21,410 Cr
P/E Ratio
PFIZER has a lower P/E
29.12x vs 29.83x
P/B Ratio
CIPLA has a lower P/B
3.36x vs 5.01x
EPS
PFIZER has higher earnings per share
₹157.72 vs ₹48.01
Dividend Yield
PFIZER has a higher dividend yield
2.83% vs 0.9%
Revenue Growth (TTM YoY)
PFIZER has faster revenue growth
6.3% vs -2.1%
EPS Growth (TTM YoY)
PFIZER has faster EPS growth
-39.6% vs -54.6%
ROE
PFIZER has a higher ROE
19.8% vs 11.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAPFIZER
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAPFIZER
Live Price₹1,410.9₹4,650
Day Change-1.51%1.23%
Volume12.88 L17,102
52-Week High₹1,673₹5,873.5
52-Week Low₹1,165.7₹4,360.1
Distance from 52W High-15.67%-20.83%

Valuation

MetricCIPLAPFIZER
Market Cap₹1.14 L Cr₹21,410 Cr
P/E Ratio29.83x29.12x
P/B Ratio3.36x5.01x
EPS₹48.01₹157.72
Book Value₹426.25₹918.74
Dividend Yield0.9%2.83%

Growth

MetricCIPLAPFIZER
Revenue Growth (TTM YoY)-2.1%6.3%
EPS Growth (TTM YoY)-54.6%-39.6%
Qtr Sales Growth-2.8%
Qtr Profit Growth-54.6%

Profitability & Leverage

MetricCIPLAPFIZER
ROE11.6%19.8%
ROCE15.5%27.2%
Net Margin13.96%28.67%
Operating Margin20.9%-12.1%
Debt to Equity0.02x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAPFIZER
Promoter Holding9.17%63.92%
FII Holding22.56% 1.37 pp1.65% 1.16 pp
DII Holding31.97% 1.25 pp17.8% 0.91 pp
Public Holding16.25% 0.12 pp16.63% 0.26 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Pfizer Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.